Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | IDH1 | O75874 | 9/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.41 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29602961 | 1.00 | DYRK1A (0.47) | DYRK1AIDH1HDAC3HDAC4HDAC1 | |
| SCHEMBL2252691 | 0.99 | DYRK1A (0.46) | DYRK1AIDH1HDAC3HDAC4HDAC1 | |
| SCHEMBL29603384 | 0.99 | DYRK1A (0.46) | DYRK1AIDH1HDAC3HDAC4HDAC1 | |
| SCHEMBL29603418 | 0.95 | DYRK1A (0.45) | DYRK1AIDH1HDAC3HDAC4HDAC1 | |
| SCHEMBL2249077 | 0.95 | DYRK1A (0.45) | DYRK1AIDH1HDAC3HDAC4HDAC1 | |
| SCHEMBL29602742 | 0.95 | DYRK1A (0.45) | DYRK1AIDH1HDAC3HDAC4HDAC1 | |
| SCHEMBL2243613 | 0.95 | DYRK1A (0.45) | DYRK1AIDH1HDAC3HDAC4HDAC1 | |
| SCHEMBL29602649 | 0.95 | DYRK1A (0.47) | DYRK1AIDH1HDAC3HDAC4HDAC1 | |
| SCHEMBL2247967 | 0.95 | DYRK1A (0.47) | DYRK1AIDH1HDAC3HDAC4HDAC1 | |
| SCHEMBL2248307 | 0.95 | DYRK1A (0.47) | DYRK1AIDH1HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312548-A1 | SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC | 2023-10-05 | — | — | US | disclosed |
| US-11649230-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2023-05-16 | — | — | US | disclosed |
| US-20220169641-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | VTVX HOLDINGS II LLC | 2022-06-02 | — | — | US | disclosed |
| US-11130753-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2021-09-28 | — | — | US | disclosed |
| US-10889580-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2021-01-12 | — | — | US | disclosed |
| US-20210002268-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | TRANSTECH PHARMA, INC. | 2021-01-07 | — | — | US | disclosed |
| US-10766888-B1 | HMOX1 inducers | MITOBRIDGE INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200148673-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | VTVX HOLDINGS II LLC | 2020-05-14 | — | — | US | disclosed |
| US-10570126-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190194181-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | TRANSTECH PHARMA, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20170189411-A9 | Compounds That Modulate Oxidative Stress | VTV THERAPEUTICS LLC | 2017-07-06 | — | — | US | disclosed |
| US-20170056413-A1 | Compounds That Modulate Oxidative Stress | VTV THERAPEUTICS LLC (US) | 2017-03-02 | — | — | US | disclosed |
| US-9447468-B2 | Compounds that modulate oxidative stress | VTV THERAPEUTICS LLC (US) | 2016-09-20 | — | — | US | disclosed |
| US-9447468-B2 | Compounds that modulate oxidative stress | VTV THERAPEUTICS LLC (US) | 2016-09-20 | — | — | US | disclosed |
| EP-2992880-A1 | Use of heme oxygenase 1 inducers and cannabinoid 2 receptor or delta-opioid receptor agonists in inflammatory pain | Fundació Institut de Recerca de l'Hospital de la Santa Creu l Sant Pau (ES) | 2016-03-09 | — | — | EP | disclosed |
| US-20140200212-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-07-17 | — | — | US | disclosed |
| US-20130253007-A1 | Compounds That Modulate Oxidative Stress | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130253007-A1 | Compounds That Modulate Oxidative Stress | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-09-26 | — | — | US | disclosed |
| US-20110201604-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201604-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169641-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GLS, HMOX2, REN | DYRK1A 3837/4885IDH1 72/4885HDAC3 499/4885 |
| US-20170189411-A9 | Compounds That Modulate Oxidative Stress | TXNRD2, GPX4, TXN2 | DYRK1A 4307/4885IDH1 1952/4885HDAC3 598/4885 |
| US-11130753-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GLS, HMOX2, REN | DYRK1A 3837/4885IDH1 72/4885HDAC3 499/4885 |
| US-20110201604-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | HMOX2, HMOX1, PTGS2 | DYRK1A 4173/4885IDH1 378/4885HDAC3 137/4885 |
| US-20230312548-A1 | SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | GLS, HMOX2, REN | DYRK1A 3860/4885IDH1 62/4885HDAC3 816/4885 |
| US-11649230-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GLS, HMOX2, REN | DYRK1A 3837/4885IDH1 72/4885HDAC3 499/4885 |
| US-20200148673-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GOT2, GLS2, PYGL | DYRK1A 4545/4885IDH1 167/4885HDAC3 203/4885 |
| US-10766888-B1 | HMOX1 inducers | HMOX1, HMOX2, HMBS | DYRK1A 4522/4885IDH1 1242/4885HDAC3 2205/4885 |
| US-20170056413-A1 | Compounds That Modulate Oxidative Stress | TXNRD2, GPX4, TXN2 | DYRK1A 4307/4885IDH1 1952/4885HDAC3 598/4885 |
| US-20190194181-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | HMOX2, HMOX1, UACA | DYRK1A 4090/4885IDH1 147/4885HDAC3 645/4885 |
| US-10889580-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GOT2, GLS2, PYGL | DYRK1A 4545/4885IDH1 167/4885HDAC3 203/4885 |
| US-20140200212-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | HMOX2, HMOX1, PTGS2 | DYRK1A 4173/4885IDH1 378/4885HDAC3 137/4885 |
| US-10570126-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | HMOX2, HMOX1, UACA | DYRK1A 4090/4885IDH1 147/4885HDAC3 645/4885 |
| US-20210002268-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GLS, HMOX2, REN | DYRK1A 3837/4885IDH1 72/4885HDAC3 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.